Takeda: Colitis, Ulcerative trials

The registry lists 66 Colitis, Ulcerative studies with Takeda as lead sponsor. 7 are open to participants now and 36 have results posted.

Phase 1 3Phase 2 10Phase 3 20Phase 4 9No phase 24(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USAAvailableNCT06856135
• A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)RecruitingNCT06764615Phase 2
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community SettingRecruitingNCT06581328Phase 4
• A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT06405087Phase 3
• A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's DiseaseRecruitingNCT06100289Phase 3
• A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingNCT05442567Phase 3
• A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South KoreaRecruitingNCT05428345
• A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)CompletedNCT04873700Results posted
• A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's DiseaseCompletedNCT04804540Phase 4Results posted
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC)CompletedNCT04779307Phase 3Results posted
• A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseActive, not recruitingNCT04738942Phase 3Results posted
• Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical OutcomesCompletedNCT04567628Results posted
• Special Drug-Use Surveillance Study on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]CompletedNCT03824561Results posted
• A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) ParticipantsCompletedNCT03710486Results posted
• A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean ParticipantsCompletedNCT03535649Results posted
• A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life PracticeCompletedNCT03532932Results posted
• A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)CompletedNCT03488030Results posted
• A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese ParticipantsCompletedNCT03329209Phase 1Results posted
• An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative ColitisCompletedNCT03290781Phase 3Results posted
• A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)CompletedNCT03283085Phase 3Results posted
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedNCT03259334Phase 3Results posted
• Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative ColitisTerminatedNCT03259308Phase 3Results posted
• Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03196427Phase 2Results posted
• Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)CompletedNCT03138655Phase 2Results posted
• Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative ColitisCompletedNCT03029143Phase 4Results posted
• Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's DiseaseTerminatedNCT02743806Phase 4Results posted
• A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's DiseaseCompletedNCT02620046Phase 3Results posted
• Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative ColitisCompletedNCT02611830Phase 3Results posted
• Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT02559713Phase 4Results posted
• An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisCompletedNCT02497469Phase 3Results posted
• Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative ColitisCompletedNCT02093663Phase 3Results posted
• Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative ColitisCompletedNCT02039505Phase 3Results posted
• Long-Term Safety Of PF-00547659 In Ulcerative ColitisCompletedNCT01771809Phase 2Results posted
• A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative ColitisCompletedNCT01620255Phase 2Results posted
• Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFsCompletedNCT01387594Phase 1Results posted
• Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative ColitisCompletedNCT01177228Phase 2Results posted
• Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative ColitisCompletedNCT01130844Phase 1Results posted
• Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative ColitisCompletedNCT01124149Phase 4Results posted
• An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00790933Phase 3Results posted
• Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative ColitisCompletedNCT00783718Phase 3Results posted
• Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's DiseaseCompletedNCT00619489Phase 2Results posted
• Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)CompletedNCT00446849Phase 4Results posted
• Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative ColitisCompletedNCT00151892Phase 3Results posted
• A Study on Infections in Adults With Ulcerative Colitis/Crohn's DiseaseWithdrawnNCT07250815
• A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06254950Phase 2
• A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)Active, not recruitingNCT06095128Phase 4
• A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in BrazilCompletedNCT05626088
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in PolandCompletedNCT05384080
• A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in SwitzerlandCompletedNCT04989907
• A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)CompletedNCT04959851
• A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real-World PracticeCompletedNCT04890262
• A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD) (VARIETY - CROATIA AND SLOVENIA)CompletedNCT04885920
• A Study of Vedolizumab in Adults in Real-World PracticeCompletedNCT04872491
• A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic PouchitisCompletedNCT04799496
• Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in EuropeCompletedNCT04597905
• A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real LifeTerminatedNCT03378388
• Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging MarketsCompletedNCT03090139
• A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)CompletedNCT02986724
• Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's DiseaseWithdrawnNCT02913508Phase 2
• Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction StudyWithdrawnNCT02760615Phase 4
• OTIS Vedolizumab Pregnancy Exposure RegistryCompletedNCT02678052
• Entyvio (Vedolizumab) Long Term Safety StudyCompletedNCT02674308
• Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative ColitisCompletedNCT00548574Phase 3
• Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476CompletedNCT00545389Phase 2
• Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative ColitisCompletedNCT00503243Phase 3
• Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis.CompletedNCT00151944Phase 3